{"id":"W2169154753","doi":"10.1016/j.bbmt.2014.12.010","title":"Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation","year":2014,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Seattle Genetics; CellGenix; Genentech; Health Resources and Services Administration; Swedish Orphan Biovitrum; Miltenyi Biotec; Kiadis Pharma; Therakos; Sigma-Tau Pharmaceuticals; Medical College of Wisconsin; Blue Cross and Blue Shield Association; Teva Pharmaceutical Industries; WellPoint; Celgene; Otsuka America Pharmaceutical; Amgen; Ariad Pharmaceuticals; GlaxoSmithKline; Terumo BCT; Leukemia and Lymphoma Society; Be The Match Foundation; U.S. Department of Health and Human Services; National Marrow Donor Program","keywords":"Busulfan; Medicine; Myeloid leukemia; Total body irradiation; Cyclophosphamide; Transplantation; Internal medicine; Oncology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002668029,0.0002270324,0.0007529908,0.0002140669,0.00004653568,0.00000302307,0.00005906503,0.000191971,0.000008742628],"category_scores_gemma":[0.0000228642,0.0001640523,0.00005310504,0.0001680139,0.0001956671,0.00009554352,0.000002908839,0.0001226684,2.708034e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001235028,"about_ca_system_score_gemma":0.000341886,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004827689,"about_ca_topic_score_gemma":0.001395035,"domain_scores_codex":[0.9985998,0.0001128132,0.0006313685,0.0002770647,0.0001606412,0.0002182733],"domain_scores_gemma":[0.9989586,0.0002927797,0.0004176947,0.0001441593,0.0001320404,0.00005471571],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008971306,0.0007172673,0.6088321,0.003079301,0.000487139,0.00000796957,0.002297076,0.0006095488,0.3613217,0.0004660983,0.00000150553,0.01320898],"study_design_scores_gemma":[0.02152892,0.009653775,0.7650787,0.0003467426,0.00124808,0.0001156197,0.0001261975,0.000604014,0.201071,0.00006721654,0.00000497579,0.0001548219],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922343,0.0002531993,0.006182359,0.00006979529,0.00004713508,0.001025168,0.0001241754,0.00001967088,0.00004414364],"genre_scores_gemma":[0.9947774,0.0005300696,0.003235822,0.0000149708,0.00001763707,0.00007493312,0.00130406,0.00002272282,0.00002236224],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1602507,"threshold_uncertainty_score":0.6689858,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01141582798629627,"score_gpt":0.2715707441943132,"score_spread":0.2601549162080169,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}